Th17 cells, a subset of CD4+ T cells that produce interleukin-17 (IL-17), play a significant role in various immune-mediated diseases, including psoriasis, rheumatoid arthritis (RA), multiple sclerosis (MS), inflammatory bowel disease, and asthma. IL-17 is a highly inflammatory cytokine that affects stromal cells in many tissues, contributing to disease pathogenesis. While Th17 cells are important for host defense against infections, their overactivity is linked to autoimmune and inflammatory disorders. The biology of Th17 cells in humans differs from that in mice, with some key differences in the signaling pathways and cytokine interactions. Th17 differentiation is influenced by TGF-β and IL-6, with additional roles for IL-23 and IL-1β in humans. Th17 cells express IL-17, IL-17F, and IL-22, and their trafficking is mediated by chemokine receptors like CCR6. Th17 cells are involved in the pathogenesis of several diseases, including psoriasis and RA, where they contribute to inflammation and tissue damage. Targeting Th17 cells with therapies such as IL-17 or IL-23 inhibitors has shown promise in treating these diseases. However, the safety of such treatments is a concern due to the role of Th17 cells in normal immune defenses. In RA, Th17 cells are involved in synovial inflammation and joint damage, and their activity is regulated by cytokines like TNF-α and IL-1β. In MS, Th17 cells are implicated in the pathogenesis of the disease, with IL-17 playing a critical role in neuroinflammation. The role of Th17 cells in other autoimmune diseases, such as systemic lupus erythematosus and reactive arthritis, is also being investigated. Understanding Th17 biology is crucial for developing effective and safe therapies for these diseases.Th17 cells, a subset of CD4+ T cells that produce interleukin-17 (IL-17), play a significant role in various immune-mediated diseases, including psoriasis, rheumatoid arthritis (RA), multiple sclerosis (MS), inflammatory bowel disease, and asthma. IL-17 is a highly inflammatory cytokine that affects stromal cells in many tissues, contributing to disease pathogenesis. While Th17 cells are important for host defense against infections, their overactivity is linked to autoimmune and inflammatory disorders. The biology of Th17 cells in humans differs from that in mice, with some key differences in the signaling pathways and cytokine interactions. Th17 differentiation is influenced by TGF-β and IL-6, with additional roles for IL-23 and IL-1β in humans. Th17 cells express IL-17, IL-17F, and IL-22, and their trafficking is mediated by chemokine receptors like CCR6. Th17 cells are involved in the pathogenesis of several diseases, including psoriasis and RA, where they contribute to inflammation and tissue damage. Targeting Th17 cells with therapies such as IL-17 or IL-23 inhibitors has shown promise in treating these diseases. However, the safety of such treatments is a concern due to the role of Th17 cells in normal immune defenses. In RA, Th17 cells are involved in synovial inflammation and joint damage, and their activity is regulated by cytokines like TNF-α and IL-1β. In MS, Th17 cells are implicated in the pathogenesis of the disease, with IL-17 playing a critical role in neuroinflammation. The role of Th17 cells in other autoimmune diseases, such as systemic lupus erythematosus and reactive arthritis, is also being investigated. Understanding Th17 biology is crucial for developing effective and safe therapies for these diseases.